BeOne Medicines (ONC) Research & Development (2015 - 2026)

BeOne Medicines (ONC) has reported Research & Development for 12 consecutive years, with $541.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Research & Development rose 12.31% year-over-year to $541.2 million; the TTM figure through Mar 2026 stood at $2.2 billion (up 11.68% YoY), while the FY2025 annual figure was $2.1 billion, up 9.86% from the prior year.
• Research & Development fell to $541.2 million in Q1 2026 per ONC's latest filing, from $615.4 million in the prior quarter.
• Across five years, Research & Development topped out at $615.4 million in Q4 2025 and bottomed at $378.2 million in Q2 2022.
• Historically, Research & Development has averaged $474.1 million across 5 years, with a median of $460.6 million in 2024.
• Annual changes were most pronounced in 2022 — Research & Development jumped 180.18% — and 2025, when it rose 4.61%.
• BeOne Medicines' Research & Development stood at $446.0 million in 2022, then advanced by 10.75% to $494.0 million in 2023, then increased by 9.72% to $542.0 million in 2024, then grew by 13.54% to $615.4 million in 2025, then declined by 12.06% to $541.2 million in 2026.
• Business Quant data shows ONC's Research & Development at $541.2 million in Q1 2026, $615.4 million in Q4 2025, and $523.7 million in Q3 2025.